NovoLog^® is the #1 selling rapid-acting insulin covered by more than 95% of managed care plans.^1,2

Benefits Include:

Helps lower A1C levels^3,4 Learn more
Mimics the body's normal mealtime insulin response⁵ Learn more
Reduces nocturnal hypoglycemia vs. regular human insulin⁶ Learn more
Available in FlexPen^® – the #1 selling prefilled insulin pen in the world² Learn more
Extended use in pump for up to 6 days Learn more
Covered for more than 95% of managed care^† patients nationwide⁷ Learn more

NovoLog^® is effective across a broad range of patients:

NovoLog^® (insulin aspart [rDNA origin] injection) is approved for pump use in children and adults.

* Needles are sold separately and may require a prescription in some states.

† Managed care plans only. Does not include Medicaid and Medicaid Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status is subject to change.

HCP Resources

With a NovoMedLink™ account you can order product samples, check formulary status and more.

Not optimized for mobile.

Indications and Usage

NovoLog^® (insulin aspart [rDNA origin] injection) is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Safety Information

NovoLog^® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog^® or one of its excipients.

NovoLog^® should generally be given immediately (within 5-10 minutes) prior to the start of a meal. As with all insulin preparations, the time course of action of NovoLog^® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. NovoLog^® should be used with a longer-acting insulin. When used in an external subcutaneous insulin infusion pump, NovoLog^® should not be mixed with any other insulin or diluent.

Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. Any change of insulin dose should be made cautiously and only under medical supervision.

Insulin, particularly when given intravenously or in settings of poor glycemic control, can cause hypokalemia. Use caution in patients predisposed to hypokalemia.

Like all insulins, NovoLog^® requirements may be reduced in patients with renal impairment or hepatic impairment.

Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog^®.

Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog^®.

Adverse reactions observed with NovoLog^® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.

Needles and NovoLog^® FlexPen^® must not be shared.

NovoLog^® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age.

The background risk of birth defects, pregnancy loss, or other adverse events that exists for all pregnancies is increased in pregnancies complicated by hyperglycemia.

Please click here for Prescribing Information.

References

IMS Health Inc. IMS National Sales Perspectives. (12 months ending December 2012).
IMS Health Inc. IMS MIDAS. (12 months ending December 2012).
Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011;17(5):727-736.
Holman RR, Farmer AJ, Davies MJ, et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736-1747.
Brange J, Vølund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 1999;35(2-3):307-335.
Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21(7):769-775.
MMIT, Formulary Compass™: August 2011.

No other rapid-acting
insulin is part of so
many lives.^1,2*